Encora Therapeutics gains FDA clearance for essential tremor device
The US Food and Drug Administration (FDA) has cleared Encora Therapeutics’ neurostimulation wearable for essential tremor (ET) management. The Massachusetts-based company’s …
Post
-
-
Abbott initiates UK pilot of Volt PFA system
Abbott has initiated a trial of its Volt pulsed-field ablation (PFA) system at 15 UK National Health Service (NHS) hospitals …
-
Neurent secures $74m to expand NEUROMARK commercial activities
Neurent Medical has closed an oversubscribed Series C financing round, raising €62.5m ($74m) to expand commercial activities for the NEUROMARK …
-
Natus Sensory acquires medical technology company TheraB Medical
Natus Sensory has purchased TheraB Medical, a US-based company specialising in neonatal wearable phototherapy devices. The acquisition aims to extend access …
-
Mira announces hormone data integration with ŌURA’s smart ring
Femtech company Mira is collaborating with ŌURA, allowing users of the Finnish company’s Oura smart ring to access lab-grade hormone …
-
Edwards reports strong 2025 despite Q4 EPS miss
Edwards Lifesciences has reported revenue over $6bn in full year 2025, predominantly driven by strong demand for its transcatheter aortic …
-
ZOLL achieves EU MDR approval for Zenix device
Asahi Kasei’s ZOLL has received approval for its Zenix monitor/defibrillator under the European Union Medical Device Regulation 2017/745 (EU MDR). The …
-
Merck and Calla Lily partner to advance Callavid platform
Merck KGaA (Merck) and Calla Lily Clinical Care have announced a strategic partnership to advance Callavid, an intravaginal drug delivery …
-
Zimmer Biomet reports 2025 revenue growth yet tempers 2026 outlook
Zimmer Biomet has achieved revenue of $8.23bn in full year 2025 off the back of continued strong demand across its …
-
UK government champions healthtech through new NHS access programme
The UK government has set out to improve access to healthcare technology within the National Health Service (NHS) through the …
-
BD shares fall by 3% after lowering FY26 profit outlook
Becton Dickinson and Company (BD) has trimmed its fiscal year 2026 (FY26) profit outlook to account for the spin-off of …
-
RWD and RWE are rewriting how we design and run trials
Traditional randomized controlled trials (RCTs) have long been the gold standard for testing new therapies, but they are increasingly strained …
-
GE HealthCare introduces ReadyFix in US to improve patient care
GE HealthCare has announced the US launch of ReadyFix, a remote fleet management solution designed to help healthcare systems optimise …
-
TransMedics receives IDE approval from FDA for OCS Heart trial
TransMedics Group has received full and unconditional investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) …
-
FDA clears Median Technologies’ lung nodule evaluation software
The US Food and Drug Administration (FDA) has cleared a lung cancer detection tool on Median Technologies’ eyonis, a suite …
